Enhanced soluble interleukin‐5 receptor alpha expression in nasal polyposis

Gevaert, Philippe; Bachert, Claus; Holtappels, Gabriële; Novo, Claudina Pérez; Heyden, José Van der; Fransen, Lucie; Depraetere, Stany; Walter, H.; Cauwenberge, Paul Van; Tavernier, Jan

doi:10.1034/j.1398-9995.2003.00110.x

Cited by 95 publications

(78 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After signing the informed consent form and a 4-to 12-week run-in period, subjects were randomized to receive 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (20 subjects) or placebo (10 subjects). Follow-up visits were scheduled 1,4,8,12,24,36, and 48 weeks after first dosing. During the follow-up visit after 4 weeks, the second injection of mepolizumab was administered (see Fig E1 in this article's Online Repository at www.jacionline.org).…”

Section: Methodsmentioning

confidence: 99%

“…Nasal secretions were obtained by placing sinus packs (IVALON 4000 plus) in both nasal cavities for exactly 5 minutes, which were immediately processed as previously described. 12 Serum and nasal secretions were assayed by means of ELISA for IL-1b, IL-5 (R&D Systems, Minneapolis, Minn), myeloperoxidase (MPO; BioCheck, Foster City, Calif), and soluble IL-5 receptor a subunit (IL-5Ra; Innogenetics, Ghent, Belgium). Eosinophil cationic protein (ECP) concentrations were obtained by using the UniCAP system (Pharmacia & Upjohn, Uppsala, Sweden), whereas IL-6 concentrations were measured with a Fluorokine MAP cytokine multiplex kit (R&D Systems) using the Bio-Rad Bio-plex 200 (Bio-Rad Laboratories, Hercules, Calif).…”

Section: Outcome Measuresmentioning

confidence: 99%

“…9,10 This cytokine seems to play a key role in the chemotaxis, activation, and survival of eosinophils. 11,12 Treatment of eosinophil-infiltrated polyp tissue with neutralizing anti-IL-5 mAb results in eosinophil apoptosis and decreases tissue eosinophilia in vitro. 10 Concerning the increased IgE level, there is increasing evidence that Staphylococcus aureus-derived enterotoxins stimulate eosinophilic inflammation through production of T H 2 cytokines and local IgE formation.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Gevaert

Bruaene

Cattaert

et al. 2011

Journal of Allergy and Clinical Immunology

569

482

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Outcome Measuresmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Gevaert

Bruaene

Cattaert

et al. 2011

Journal of Allergy and Clinical Immunology

569

482

View full text Add to dashboard Cite

“…Reslizumab (SCH55700; Teva Pharmaceuticals, Petah Tikva, Israel) is a humanised IL-5 monoclonal antibody that has been previously investigated in the treatment of nasal polyps and is currently in clinical development for the treatment of asthma [46]. Reslizumab administered over 12 weeks failed to improve asthma control in 18 patients with severe uncontrolled asthma and sputum eosinophilia compared to eight patients who served as controls [40].…”

Section: Reslizumabmentioning

confidence: 99%

Anti-interleukin-5 therapy in severe asthma

et al. 2013

View full text Add to dashboard Cite

Asthma is a chronic inflammatory disorder of the airways that leads to acute symptoms, exacerbations and sometimes, for a small part of the asthmatic population, fatal or near-fatal exacerbations.This as yet significant minority of individuals present with severe asthma and have persisting daily symptoms, and exacerbations despite compliance with high doses of inhaled steroids and additional treatment. For more than a decade, the pharmacological management of patients with severe asthma has focused on evaluating specific cytokines. The rationale of this approach is based on the distinguished key role played by eosinophils in the asthma inflammatory processes. Eosinophils are recruited from the circulation to airways where they cause airway damage via different mechanisms. Eosinophils are regulated in terms of their recruitment, activation, growth, differentiation and survival by interleukin (IL)-5. Abundant data from in vitro experiments, animal models and clinical trials has confirmed that IL-5 inhibition may be an effective approach for the treatment of asthma, especially severe asthma. Interfering with eosinophil function or reducing their numbers has been one of the most important goals of therapeutic monoclonal antibodies, which target cytokine receptor interactions in asthma, particularly IL-5. This review will consider new treatments options for severe asthma, particularly those targeting IL-5, that have already been evaluated in clinical trials in asthmatic patients. @ERSpublications Rationale, recent advances and future developments of anti-IL-5 therapy in patients with severe asthma http://ow.ly/n3viv

show abstract

“…Eosinophil and polyp structural cells secrete cytokines that maintain the inflammation process and the Eosinophil build up constant. 8 Cytokines such as IL5 and GM-CSF increase eosinophil survival and prolong their presence within the polypoid tissue, reducing the apoptosis rates of these cells [9][10][11][12] . Eosinophils express CD40 receptor for this GM-CSF and CD40L autocrine production and they are expressed by T CD4 cells that are present in eosinophilic NSP 13 .…”

Section: Introductionmentioning

confidence: 99%

Efeito da mitomicina C em polipose nasossinusal eosinofílica, in vivo: dosagem de IL5 e GM-CSF, RT-PCR

Assunção

Castro²,

Araújo³

et al. 2006

Rev. Bras. Otorrinolaringol.

View full text Add to dashboard Cite

Eosi nophilic nasosinusal polyposis is a chronic inflammatory infection with elevated infiltration of eosinophils, which presents high rate of recurrence after surgical treatment. The continuous inflammatory process that leads to the formation of polyps requires constant clinical treatment. Contributing to the maintenance of eosinophilia are cytokines IL5 (interleukin-5) and GM-CSF (granulocyte macrophages colony-stimulating factor), which show up in elevated concentrations. These oligoproteins diminish the rate of apoptosis and prolong the survival of eosinophils. Aim: By diminishing these cytokines, the action of Mitomycin C (MMC), an antineoplasic drug which inhibits the synthesis of DNA, was studied. In a recent study the power of this drug to cause apoptosis in eosinophils, in vitro, of nasal polyps was verified. Methodology: A biopsy of the nasal polyps was undertaken in 15 patients carriers of eosinophilic nasosinusal polyposis 24 hours after applying 0.5 mg/ml of MMC during five minutes. RT-PCR (reverse transcription of polymerase chain reaction) for IL5 and GM-CSF was the method used to obtain the results. Results: The comparison of the results of GM-CSF pre-and post-application of MMC, when the paired T-test was used, showed p=0.041 and for IL5 we found p<0.001. Conclusion: Topic use of MMC in patients with eosinophilic nasosinusal polyposis shows statistically significant reduction for GM-CSF and significant and important reduction for IL5.

show abstract

Enhanced soluble interleukin‐5 receptor alpha expression in nasal polyposis

Cited by 95 publications

References 21 publications

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Anti-interleukin-5 therapy in severe asthma

Efeito da mitomicina C em polipose nasossinusal eosinofílica, in vivo: dosagem de IL5 e GM-CSF, RT-PCR

Contact Info

Product

Resources

About